Investigational drug · Phase 2
BBI-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hereditary Hemochromatosis.
Phase 2Last checked: Nov 19, 2026Latest source record: May 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BBI-001"
First trial start
2026
May 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BBI-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Hemochromatosis
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BBI-001" as an intervention, largest first.
- A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary HemochromatosisRecruiting
Bond BiosciencesIndustry
NCT07371793 · 34 participants (planned) · Start May 4, 2026 · Primary completion Feb 2027
Drug: BBI-001 · For: Hereditary Hemochromatosis
Sites: Sydney, Australia
Bond BiosciencesIndustry
NCT05238207 · 24 participants · Start Mar 28, 2022 · Primary completion May 4, 2023
Drug: BBI-001 · For: Hereditary Hemochromatosis
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload.
Scribner C, Cope J, Ryan P, et al. · Sci Rep 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.